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ABSTRACT 
Research in present time has been focusing on finding a specific SARS-CoV-2 vaccine or antiviral, which will probably be the 
therapeutic goal in the fight against the virus. In the meantime, scientific evidence shows that it is possible to have effective 
clinical improvements of infected patients in reducing the strong hyperinflammatory state. The SARS-CoV-2 infection is divided 
into three stages. The most serious phase is the third one where the immune system overdrives and launches an intense attack 
against itself. This is called "cytokine storm" and leads to tissue damage and often to death. Stopping the cytokine storm early is 
definitely an effective move; since March several studies have been evaluating how this can be an important pharmacological 
aspect. Blocking IL-6 or IL-1 inhibitors, for example, is already known to have wide efficacy, but they are not alone in being able 
to block the cascade of cytokines. This is a clinical pharmacology article and demonstrates how the use of colchicine, monotherapy 
or in combination in all three phases of SARS-CoV-2, controls inflammation and prevents patient death. Colchicine is safe and 
effective for treating SARS-CoV-2 patients in preventing inflammation and lung collapse and is certainly useful as an added 
remedy for other drugs. The advantage is certainly its safety profile much higher than that provided by other drugs, such as 
corticosteroids and immunosuppressive drugs. Note is the story of hydroxychloroquine: use has been banned due to its high 
toxicity. 
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INTRODUCTION 
At the end of 2019, a new coronavirus identified as 
SARS-CoV-2 was contracted in China and caused 
thousands of pneumonia resulting in deaths. It quickly 
spread all over the world. Much has been understood 
about SARS-CoV-2 and its pathogenesis. SARS-CoV-
2 infection can be divided into three phases: phase 1, 
asymptomatic period that does not require 
hospitalization; phase 2, slightly symptomatic period 
with virus detection; phase 3, severe symptomatic 
phase and strong hyper inflammatory state. Phase 3 is 
most serious and dangerous because the strong 
inflammation causes lethal pneumonia due to a large 
release of cytokines defined as "cytokine storm"(CS)
1,2
. 
Phases of SARS-CoV-2 infection 
For each pathological phase, a specific therapeutic 
treatment can be indicated or avoided. Every single 
phase must be well identified from patient to patient 
because the therapeutic approach is different
3,4
.  
 
Phase 1 (or non-serious phase)  
At this stage the patient is infected and the immune 
system tries to counter it. This phase lasts between 
three and seven days. At this stage, an immune 
response is required that is suitable for breaking down 
the virus and avoiding progression in the later stages of 
the disease. The use of an antiviral to lower the viral 
load is definitely helpful and would stimulate the 
immune system to react effectively. Encouraging 
evidence of efficacy concerns remdesivir, 
lopinavir/ritonavir, chloroquine and hydroxychloro- 
quine. If the virus is defeated at this stage there is an 
easy clinical recovery
5,6
. 
Phase 2 (moderate) 
The second stage of infection occurs between the tenth 
and fourteenth days. The protective immune response 
has failed and the virus cannot be defeated. The deep 
respiratory tract is the tissue that is exposed to the 
greatest risk of pneumonia
7,8
. This is also called the 
hypoxic phase with urgent hospitalization. Heart and 
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clotting problems they are frequent, leading the patient 
to aggravate his clinical picture. Laboratory tests show 
a marked increase in pro-inflammatory molecules. Co-
combined treatment of antiviral, oxygen and anti-
inflammatory drugs is the ideal solution to treat these 
patients, the administration of low molecular weight 
heparin should always be used to prevent 
thromboembolic events
9,10
. 
Phase 3 (severe) 
The third stage leads to the patient's death and is 
therefore the most serious. The hyperactive 
inflammatory state called Cytokine Storm (CS) quickly 
leads the patient to respiratory distress syndrome 
(ARDS)
11,12
. In this phase the values of the 
proinflammatory molecules (IL-2, IL-6, GCSF, TNF-
alpha, D-dimer, ferritin, etc.) are very high with severe 
respiratory insufficiency and cardiac shock. 
Immunological therapies (corticosteroids, anti-
interleukin 6, such as tocilizumab and sarilumab, IL-1 
receptor antagonists such as anakinra or canakinumab, 
JAK inhibitors, convalescent plasma) are needed in this 
phase to reduce the inflammatory response triggered by 
cytokines. The prognosis is obviously very serious
13,14
. 
Table 1: Trials on going with colchicine in SARS-Cov-2 patients.(Clinicaltrials.gov) 
Row Study Title Conditions 
1 Colchicine Coronavirus SARS-CoV2 
Trial (COLCORONA) 
Corona Virus Infection 
2 The GReek Study in the Effects of 
Colchicine in Covid-19 
Corona Virus Disease 19 
(SARS-Cov 2) 
3 Colchicine Efficacy in COVID-19 
Pneumonia 
Corona Virus Infections 
Pneumonia Viral 
4 The ECLA PHRI COLCOVID TRIAL SARS-Cov-2 infection 
5 Colchicine Counteracting 
Inflammation in COVID-19 
Pneumonia (ColCOVID-19) 
SARS-Cov-2 
6 Treatment with colchicine of patients 
affected by Covid-19:a pilot Study” 
SARS-Cov-2 
 
Colchicine 
Colchicine is a well-known drug and used in various 
therapies such as family Mediterranean fever (FMF) in 
which it has the greatest clinical success, in addition to 
traditional anti-gout use
15
. The anti-inflammatory 
properties of the drug make it suitable for its use in 
SARS-CoV-2 infection by interfering in the cascade of 
cytokines at different levels with multiple mechanisms. 
Binding the tubulin molecule and therefore inhibiting 
its polymerization as microtubules in neutrophils is the 
main mechanism of action, thus migration is inhibited. 
In addition, the formation of adhesion molecules is 
altered, leading to a strong inhibition of the interaction 
between white blood cells and endothelial cells. For 
these reasons, the anti-inflammatory effect has multiple 
mechanisms of action
16
. The beneficial effects in 
SARS-CoV-2 are probably due to the inhibition of IL-
1, IL-6 and IL-18 because colchicine can interfere with 
the inflammatory protein complex NLRP3 which is 
primarily responsible for the release of cytokines.  
The NLRP3 inflammasome is activated in various 
ways and has a major role in the development of the 
cytokinin storm from SARS-CoV-2. Its upstream 
inhibition can be considered as prevention or treatment 
of SARS-CoV-2. Many clinical trials are currently 
underway to investigate the use of colchicine in 
positive Covid patients, as detailed in Table 1. 
Colchicine (at a dose of 0.5-2 mg/day) is the gold 
standard drug in FMF prophylaxis
17
. Extending the use 
of colchicine to SARS-Cov2 is closely related to its 
main indication. FMF is an inherited autoinflammatory 
disease with febrile episodes (attacks) and severe 
inflammation. The use of colchicine (max 3 mg / day) 
is proven to have an efficacy in preventing 
inflammatory attacks
18
. Based on its safe and known 
tolerability profile after many years of clinical practice, 
this drug can be used both as monotherapy and in 
combination in all three stages of coronavirus infection 
as shown in Table 2. 
Table 2: Hypothetical timing of clinical 
pharmacological management of the inflammatory 
state in the SARS-Cov-2 patient 
 Phase 1 Phase 2 Phase 3 
COL Prophylaxis Treatment Treatment 
HCQ  Treatment Treatment 
TCZ/SAR  Treatment? Treatment 
 
Colchicine as monotherapy in phase 1 and for 
complications prevention in phase 2 or 3 
The drug used in common doses, according to the 
existing literature that narrates the effective treatments 
in FMF, is a good remedy in phase 1 of the positive 
covid pathology. Practically a low initial dose (0.5 mg / 
day) can be used as a preventive method to avoid going 
to the next stages. This therapy can also be used in 
combination with antivirals to reduce virus replication 
pending the immune system's reaction to the infection. 
At standard doses colchicine, unlike other drugs, has a 
good tolerability profile and this is very important to 
combat the first phase where you must avoid 
administering immunosuppressants or glucocorticoids 
because they depress the immune system
19,20
. 
Colchicine as monotherapy or in combination for 
phase 2 treatment  
This phase is crucial and therapy should be carefully 
decided based on the patient's clinical condition. 
Antivirals at this stage could have their use even if 
therapeutic interactions and adverse effects need to be 
monitored. Based on clinical analyzes, the variation in 
doses of colchicine is an appropriate strategy to be put 
in place: bring the dose of 0.5 mg twice a day if the 
patient is an adult with a body weight greater than 70 
kg. Another therapeutic approach is the combination of 
colchicine always at 0.5 mg with hydroxychloroquine 
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in low doses to avoid toxic effects. Colchicine and 
hydroxychloroquine have synergistic action on 
inflammation and in addition there is also the antiviral 
action of hydroxychloroquine to support it in phase 2
21
. 
(Figure 1) The use of anti IL6 or anti IL1 or 
glucocorticoids should be considered based on the 
patient's clinical picture
22
. 
 
Figure 1: Pharmacological synergism of the 
association colchicine-chloroquine 
 
Colchicine in association for phase 3 treatment  
Slowing down or blocking the uncontrolled 
inflammatory response is the main objective of this 
pathological phase in which the release of cytokines 
occurs. Antiviral treatments are overshadowed and 
their benefits at this level are quite questionable as the 
risks of the benefits are highe
23
r.  
 
Figure 2: Pharmacological synergism of the 
association colchicine-inibhitors IL-6 
 
Anti-inflammatory therapy must be further 
strengthened to avoid patient death. There are many 
anti-inflammatory drugs, including non-steroidal anti-
inflammatory drugs, glucocorticoids, immune-
modulators
24
. While the use of glucocorticoids appears 
to be of little use also in relation to the dose to be used, 
the use of cytokine inhibitors such as tocilizumab (IL-6 
inhibitor) or anakinra (IL-1 receptor antagonist) have 
shown good efficacy in numerous studies even if 
precise efficacy doses have not been identified. The 
expert opinions of the past few months are constantly 
overlapping
25
. The main concern, of course, is that 
immunomodulatory drugs increase the risk of 
infections and therefore there is the risk of delaying the 
elimination of the virus and risking the appearance of 
secondary infections. The IL-6 tocilizumab and 
sarilumab inhibitors have shown good anti-
inflammatory efficacy and are therefore used in 
rheumatoid arthritis. In addition, on August 30, 2017, 
Tocilizumab was approved for cytokine release 
syndrome in the United States and studies are 
underway to evaluate its use in FMF, just like 
colchicine
26
. This we don't think is a coincidence. 
Colchicine (0.5 mg once or twice a day), alone or in 
combination with IL6 inhibitors to control CS, can 
make significant clinical progress
27
. The advantage of 
colchicine compared to other drugs is represented by 
the inflammatory block upstream of all cytokines and 
not just one and also has a safe safety profile. The 
combination of colchicine and IL-6 inhibitors can show 
a synergistic action as shown in Figure 2 (15-28)
28
. 
 
CONCLUSION 
SARS-CoV-2 infection can be divided into three 
phases, respectively: asymptomatic or slightly 
symptomatic incubation period with or without 
detectable viruses; slightly symptomatic period with 
the presence of viruses; severely symptomatic 
respiratory phase with high viral load and generalized 
hyperinflammatory state characterized by a sudden 
release of cytokines in the circulation defined as 
"cytokine storm" (CS).  The combination of different 
drugs, at doses below monotherapy, may be the most 
effective and tolerable solution to change the patient's 
inflammatory state, particularly in the second and third 
phases. 
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